Aviceda Therapeutics submitted an investigational new drug application to the FDA for AVD-104 for the treatment of geographic atrophy secondary to age-related macular degeneration.
The submission is supported by positive safety data for multiple doses of AVD-104 (glycan-coated nanoparticle) across IND-enabling Good Laboratory Practice toxicity studies, including dose-range finding studies in non-human primates and rabbits, according to a press release. The company is aiming to initiate phase 2 human clinical trials of the intravitreal nanoparticle.
Additionally, Aviceda submitted a fast track